Press Release Pharnext Announces PXT3003 for the Treatment of CharcotMarie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) […]
Continue ReadingThe following advice was given to CMTUK by the team at Queen’s Square and has been reviewed by Professor Mary […]
Continue ReadingThe first ever Rare Film Festival took place on 10th February at the Regent Street Cinema Over 50 films were […]
Continue ReadingPharnext Announces Encouraging Data from Open ‐ Label Phase 3 Extension Study of PXT3003
Continue ReadingCRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
Continue Reading2019.08.30_PXT3003_US_FDA_EN
Continue ReadingLast Updated: Tuesday 16th April, 2024